Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy
Background/Aims Safety for tumor necrosis factor inhibitors (TNFi) in cancer has been focused on risk of incident malignancies, but studies on prognostic effects have been scarce. We determined survival and recurrence rates at 1, 2, and 5 years after cancer diagnosis in patients with and without con...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Korean Association for the Study of Intestinal Diseases
2020-07-01
|
| Collection: | Intestinal Research |
| Sujets: | |
| Accès en ligne: | http://www.irjournal.org/upload/pdf/ir-2019-09140.pdf |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|